CDMO News
ImmunoPrecise Antibodies Partners with RIBOPRO to Advance AI-Driven Antibody Discovery
ImmunoPrecise Antibodies Ltd. (IPA) has announced a collaboration with RIBOPRO to improve the discovery and development of therapeutic antibodies. The partnership will integrate RIBOPRO’s expertise in mRNA sequence optimisation and LNP-based delivery with IPA’s advanced B-cell screening, single-cell analysis, and AI-driven discovery workflows.
27 February 2025